Bluebird Bio to Lay Off 25% of Workforce
About a month after reporting it’s had a tough time starting enough patients on its treatments, bluebird bio announced it will lay off about 25% of its employees, over half of whom work in R&D.
Uncategorized
Boehringer, Insilico Appear to Break Through Against IPF
Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary fibrosis, an intractable lung disease for which current treatment options fail to stop progression, but the data were limited, leaving experts wanting.
Boehringer, Insilico Appear to Break Through Against IPF Read More »
Flagship’s AI Company Generate Inks Deal Worth up to $1B With Novartis
Flagship Pioneering–backed Generate:Biomedicines has signed its second major Big Pharma partnership, bringing in $65 million upfront to use its AI platform to discover novel protein drug candidates.
Flagship’s AI Company Generate Inks Deal Worth up to $1B With Novartis Read More »
El Big data y su impacto en el medio ambiente y la sostenibilidad
El big data es una tendencia que ha revolucionado el mundo de la tecnología y los negocios en los últimos años. Se refiere a la capacidad de manejar grandes cantidades de datos de manera eficiente y analizarlos para obtener información valiosa. Esta información pue …
El Big data y su impacto en el medio ambiente y la sostenibilidad Read More »
The White House, Microsoft, SAS, Foley Hoag & Astellas Offer AI Guidance to Investors. Part Two: The Future
As technology continues to evolve, companies should have strategies that incorporate an understand of where they are now, where they want to be, and do they have the talent to get there.
Amgen Gets Legal Win in Eylea Patent Row With Regeneron
Regeneron’s lawsuit, filed earlier this year, alleged more than 30 counts of patent infringement against Amgen and its biosimilar to the blockbuster eye therapy Eylea.
Amgen Gets Legal Win in Eylea Patent Row With Regeneron Read More »
Biogen, UCB Score Phase III Lupus Victory After Mid-Stage Stumble
Stifel analyst Paul Matteis called Tuesday’s readout a “positive surprise” that could reinvigorate some investor enthusiasm for Biogen as the company “has essentially become an out-of-favor value stock,” driven by the slow launch of its Alzheimer’s disease therapy Leqembi.
Biogen, UCB Score Phase III Lupus Victory After Mid-Stage Stumble Read More »
Biohaven Sets Stage for Comeback With Pivotal Study Results in Spinocerebellar Ataxia
The FDA previously refused to review Biohaven’s candidate in the indication due to a failed late-stage trial. However, the company is now planning to file an NDA in the fourth quarter of 2024.
Biohaven Sets Stage for Comeback With Pivotal Study Results in Spinocerebellar Ataxia Read More »
Amgen, Lilly Are Part of Ongoing Senate Probe Into Pharma’s Restrictions on 340B Program
A senior senator has asked the CEOs of both companies to provide information about the limits they are putting on 340B drug pricing for hospitals.
Amgen, Lilly Are Part of Ongoing Senate Probe Into Pharma’s Restrictions on 340B Program Read More »
Descubren un inesperado papel del sodio en la generación de energía por las mitocondrias
Unos científicos han revelado una función crucial del sodio en la generación de energía celular. El estudio lo ha realizado un equipo que incluye al grupo de investigación GENOXPHOS del Centro Nacional de Investigaciones Cardiovasculares (CNIC) y del Centr …
Descubren un inesperado papel del sodio en la generación de energía por las mitocondrias Read More »